July 15, 2023

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the $43

Bridge­Bio said it would share da­ta on a crit­i­cal Phase III tri­al on Mon­day morn­ing, in what’s ex­pect­ed to be a make-or-break mo­ment for the

The FDA iden­ti­fied is­sues with main­te­nance and clean­ing at a Catal­ent man­u­fac­tur­ing fa­cil­i­ty re­spon­si­ble for the FDA re­jec­tion of a new ver­sion of Re­gen­eron’s block­buster

The House of Rep­re­sen­ta­tives passed its wide-reach­ing de­fense spend­ing bill Fri­day on a large­ly par­ty-line vote, green­light­ing a bi­par­ti­san pro­vi­sion that would di­rect the De­part­ment

Com­pa­nies that make re­gen­er­a­tive med­i­cines like CAR-T ther­a­pies, gene-edit­ed stem cells and eye im­plants face a num­ber of chal­lenges that lim­it the de­vel­op­ment and use

No­vo Nordisk said a sec­ond man­u­fac­tur­er is now ready to be­gin pro­duc­tion for its in-de­mand weight loss drug We­govy, with a third site on the

The UK’s phar­ma in­dus­try group is warn­ing of a dire sit­u­a­tion for the coun­try’s life sci­ences sec­tor, which saw a $1.1 bil­lion (£0.9 bil­lion) re­duc­tion

Mark Cuban’s Cost Plus Drug Com­pa­ny is bring­ing an­oth­er brand-name type 2 di­a­betes treat­ment un­der its wing. Ther­a­cos­Bio’s re­cent­ly ap­proved SGLT2 in­hibitor Bren­zavvy is now